ALX Oncology Holdings Inc., a prominent immuno-oncology firm with specialization in the development of therapies to suppress the CD47 immune checkpoint pathway, has recently embarked on a Phase 2 investigator-sponsored trial (IST). The primary of this study is to investigate the efficacy of a neoadjuvant radiation and evorpacept an innovative CD47 blocker when combined with Pembrolizumab (KEYTRUDA) in patients suffering from HPV-Mediated Oropharyngeal Cancer (HPVOC) who have not undergone any previous treatment. The trial has been initiated to involve patients with early-stage locally advanced, resectable HPVOC. Evorpacept is a next-generation CD47 blocker and its combination with Pembrolizumab, an antibody...

Evaluation of Evorpacept in Combination with Standard-of-Care in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma: A Promising Treatment Option

:This article aims to assess the clinical data reported by ALX Oncology regarding the use of evorpacept in combination with standard-of-care treatment in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL). The study involved twenty patients with indolent and aggressive R/R B-NHL who received evorpacept in combination with rituximab and lenalidomide (R2). The study findings indicate that this combination therapy was well-tolerated, displaying a safety profile comparable to historical R2 treatment. Furthermore, initial activity results demonstrated a notable best overall response rate (ORR) of 94% and a complete response rate (CRR) of 83% in patients with indolent R/R B-NHL. These fin...

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com